LGND vs. ARCT, PRAX, NRIX, TVTX, CMPS, HALO, IONS, MDGL, ALKS, and FOLD
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Arcturus Therapeutics (ARCT), Praxis Precision Medicines (PRAX), Nurix Therapeutics (NRIX), Travere Therapeutics (TVTX), COMPASS Pathways (CMPS), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), and Amicus Therapeutics (FOLD). These companies are all part of the "medical" sector.
Arcturus Therapeutics (NASDAQ:ARCT) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Ligand Pharmaceuticals has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics currently has a consensus target price of $64.86, suggesting a potential upside of 67.11%. Ligand Pharmaceuticals has a consensus target price of $116.33, suggesting a potential upside of 36.78%. Given Ligand Pharmaceuticals' higher probable upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Ligand Pharmaceuticals.
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 13.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 5.9% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Arcturus Therapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
In the previous week, Arcturus Therapeutics had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 2 mentions for Ligand Pharmaceuticals. Arcturus Therapeutics' average media sentiment score of 1.21 beat Ligand Pharmaceuticals' score of 1.06 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.
Ligand Pharmaceuticals received 103 more outperform votes than Arcturus Therapeutics when rated by MarketBeat users. Likewise, 69.96% of users gave Ligand Pharmaceuticals an outperform vote while only 65.44% of users gave Arcturus Therapeutics an outperform vote.
Ligand Pharmaceuticals has a net margin of 79.30% compared to Ligand Pharmaceuticals' net margin of -81.59%. Arcturus Therapeutics' return on equity of 8.52% beat Ligand Pharmaceuticals' return on equity.
Summary
Ligand Pharmaceuticals beats Arcturus Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
